Numerous studies have demonstrated that the hypothalamic ventromedial nuclei (VMN) regulate energy homeostasis by integrating and utilizing behavioral and metabolic mechanisms. The VMN heavily express pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptors (PAC1R). Despite the receptor distribution, most PACAP experiments investigating affects on feeding have focused on intracerebroventricular administration or global knockout mice. To identify the specific contribution of PACAP signaling in the VMN, we injected PACAP directly into the VMN and measured feeding behavior and indices of energy expenditure. Following an acute injection of PACAP, nocturnal food intake was significantly reduced for 6 h after injections without evidence of malaise. In addition, PACAP-induced suppression of feeding also occurred following an overnight fast and could be blocked by a specific PAC1R antagonist. Metabolically, VMN-specific injections of PACAP significantly increased both core body temperature and spontaneous locomotor activity with a concurrent increase in brown adipose uncoupling protein 1 mRNA expression. To determine which signaling pathways were responsive to PACAP administration into the VMN, we measured mRNA expression of well-characterized hypothalamic neuropeptide regulators of feeding. One hour after PACAP administration, expression of proopiomelanocortin mRNA was significantly increased in the arcuate nuclei (ARC), with no changes in neuropeptide Y and agouti-related polypeptide mRNA levels. This suggests that PAC1R expressing VMN neurons projecting to pro-opiomelanocortin neurons contribute to hypophagia by involving melanocortin signaling. While the VMN also abundantly express PACAP protein, the present study demonstrates that PACAP input to the VMN can influence the control of energy homeostasis. feeding; energy expenditure; pro-opiomelanocortin; rat THE VENTROMEDIAL NUCLEI (VMN) of the hypothalamus function to regulate energy homeostasis by affecting both food intake and energy expenditure. In rats, stimulation of the VMN inhibits feeding and promotes metabolism through the sympathetic nervous system (2, 47, 49, 52), whereas VMN lesions lead to hyperphagia, obesity, and metabolic insufficiency (9 -11, 31). The VMN contain numerous receptor populations for signals known to influence feeding and metabolism, including glucose, insulin, neuropeptide Y (NPY), and leptin, among others (3, 8, 13, 16, 33) . For example, elimination of leptin signaling specifically in VMN neurons produces an obese phenotype, suggesting that the VMN are significant targets of leptin-mediated energy homeostasis (16). By contrast, less is known about specific cell types within the VMN that are responsive to such signals. Confirmed neuronal populations within this cell group include glutamate, enkephalin, and the VMN-enriched neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) (23, 25, 29, 64) .
THE VENTROMEDIAL NUCLEI (VMN) of the hypothalamus function to regulate energy homeostasis by affecting both food intake and energy expenditure. In rats, stimulation of the VMN inhibits feeding and promotes metabolism through the sympathetic nervous system (2, 47, 49, 52) , whereas VMN lesions lead to hyperphagia, obesity, and metabolic insufficiency (9 -11, 31) . The VMN contain numerous receptor populations for signals known to influence feeding and metabolism, including glucose, insulin, neuropeptide Y (NPY), and leptin, among others (3, 8, 13, 16, 33) . For example, elimination of leptin signaling specifically in VMN neurons produces an obese phenotype, suggesting that the VMN are significant targets of leptin-mediated energy homeostasis (16) . By contrast, less is known about specific cell types within the VMN that are responsive to such signals. Confirmed neuronal populations within this cell group include glutamate, enkephalin, and the VMN-enriched neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) (23, 25, 29, 64) .
PACAP is a 38 amino acid neuropeptide that belongs to the secretin super family of peptides (24, 58) . PACAP binds to the PACAP receptor (PAC1R), and the receptors for vasoactive intestinal polypeptide (VIP), VPAC1 and VPAC2. PACAP binds to PAC1R with an approximately twofold higher affinity compared with the VIP receptors, while VIP does not bind to PAC1R (17) . PAC1R is a G protein-coupled receptor that can stimulate adenylate cyclase activity; however, the receptor is heavily alternatively spliced, and several PAC1R splice variants have been shown to activate other secondary messenger pathways (57) . Much of the work thus far involving PACAP and feeding behavior has focused on intracerebroventricular injections or global knockouts, neither of which can speak to specific sites of action by which PACAP induces its effects (1, 27, 38, 41, 45, 53, 54, 56) . PACAP administered intracerebroventricularly produces a robust decrease in food intake with the accompaniment of increased energy expenditure (7, 27, 38, 41, 45) . Although PAC1R mRNA expression is widespread throughout the central nervous system, a brain region with abundant expression is the hypothalamus (see Fig. 6 ), specifically in the dorsomedial nuclei (DMN), VMN, and arcuate nuclei (ARC) (26) . Additionally, PACAP mRNA is also heavily concentrated in the VMN (23) . Recently, evidence suggesting VMN PACAP signaling regulates energy homeostasis has been demonstrated by studies showing that mRNA expression of PACAP in the VMN during a 48-h fast decreases, while treatment with a chronic high-fat diet causes an increase in VMN PACAP mRNA in CD1 mice (27, 41) . These data imply that, within the VMN, PACAP signaling is sensitive and responsive to the nutritional status of the animal.
Given its discrete and abundant expression within the VMN, PACAP and its receptor may yield novel mechanisms for the control of feeding and energy expenditure. Cells of the VMN express abundant amounts of PAC1R mRNA, and contribute to the normal function of feeding behavior and energy homeostasis (26, 31) . Therefore, to further investigate the importance of highly localized PAC1R signaling, we directly microinjected PACAP into the VMN and subsequently measured feeding behavior, as well as cellular and metabolic responses. Finally, we confirmed that the hypophagic responses were 1) mediated through the PAC1R subtype and 2) not a product of malaise. Our studies demonstrate that PACAP signaling within the hypothalamic VMN promotes a negative energy state by decreasing feeding and stimulating metabolic systems that promote energy expenditure.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were individually housed in a climate-controlled room with a 12:12-h light-dark cycle (lights on at 0500 h). Animals had free access to Harlan standard diet (8604 formulation) and water, unless stated otherwise in specific experiments. Food consumption was measured with a BioDAQ Food Intake Monitor (Research Diets; New Brunswick, NJ) or calculated by preweighing food in each bin and subtracting the weight of noningested and spilled food at the end of each measurement period. All procedures using animals were approved by the Marquette University Institutional Animal Care and Use Committee.
Surgery
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 mg·ml Ϫ1 ·kg Ϫ1 ip) cocktail and placed in a stereotaxic apparatus. Next, 26-gauge bilateral guide cannulae (Plastics One; Roanoke VA) were placed 3 mm dorsal to the hypothalamic VMN in all animals and secured to the surface of the skull with an acrylic resin. The stereotaxic coordinates for the VMN injection site were 1) anterior/ posterior, Ϫ2.5 mm from bregma; 2) medial/lateral, Ϯ 0.6 mm from midline; 3) dorsal/ventral, Ϫ9.2 mm from surface of the skull based on Paxinos and Watson (46) . Injectors extended 3 mm past the ventral tip of the cannulae, reaching an injection site of Ϫ9.2 mm ventral from the surface of the skull. The upper incisor bar was positioned Ϫ3.3 mm below horizontal zero. A bilateral dummy stylet placed in the guide cannulae was used to maintain patency. The animals were given at least 5 days to recover after cannulae installation before receiving drug or vehicle injections during which time the animals were handled and guide cannulae were removed and replaced daily to acclimate the animals to the physical handling necessary during the experiment. Correct cannulae placements were confirmed at the conclusion of each experiment by microscopic examination of Nissl stained sections and only those with correct placement were included in the studies.
Microinjections and Injection Spread
In all experiments, 0.25 l/side of PACAP (PACAP38; California Peptide Research, Napa, CA) or saline was microinjected through bilateral guide cannulae over ϳ2 min in awake animals. Following each injection, an additional minute elapsed before removal of injectors to minimize backflow of injected material. At the completion of each experiment, following rapid decapitation, brains were collected for in situ hybridization or confirmation of cannulae placement. The optimal spread of injection within the VMN was determined using different volumes (0.1, 0.25 l) of biotinylated PACAP (PACAP38-Biotin; Anaspec, Fremont, CA). One hour following biotinylated PACAP injections, animals were anesthetized with a ketamine/xylazine/acepromazine cocktail, and transcardially perfused with 0.9% NaCl and 4% paraformaldehyde in PBS. Brains were removed, sucrose embedded, and sectioned on a freezing microtome at 30 m and stored in cryoprotectant solution at Ϫ20°C. Brain sections containing the injection sites and surrounding areas were then immunohistochemically stained using a primary antibody against biotin. Immunohistochemical signal was then compared with the cresyl violet staining of adjacent sections to determine surgical accuracy and the spread of the biotinylated PACAP injection within the VMN.
Experiments
Feeding behavior. Animals (n ϭ 4 per group) were acclimated to the BioDAQ Food Intake Monitor for at least 7 days before the onset of the experiment. Approximately 2 h prior to lights off, rats were weighed and injected bilaterally with vehicle, 25 pmol PACAP, or 50 pmol PACAP. Feeding measurements were collected for the next 18 h at which time body weights were measured again. Afterward, brains were collected to confirm cannula placement as well as retroperitoneal (including perirenal; rWAT) and epididymal white adipose tissue (eWAT), and interscapular brown adipose tissue (iBAT). iBAT was cleaned of WAT for measurement of uncoupling protein 1 (UCP1) mRNA content.
To examine effects of PACAP on feeding behavior following an overnight fast, a separate cohort of animals (n ϭ 10 per group) was used. Food was removed from all animals just prior to lights off (1700 h) the day before the experiment. The following morning (ϳ16 h later) animals received bilateral injections of vehicle or 50 pmol PACAP. At 10 min after the injection, food was returned and feeding was measured for the next hour.
Conditioned flavor avoidance. To determine whether PACAPinduced hypophagia in the VMN was a consequence of malaise, a conditioned flavor avoidance (CFA) behavioral paradigm was used (15, 48) . A baseline experiment was performed by water-depriving naïve rats for 22 h, and giving the animals a two-bottle choice test with one bottle containing novel vanilla-flavored water (0.5% McCormick vanilla extract) and the other bottle containing novel almond-flavored water (0.5% McCormick almond extract). For the CFA test, rats (n ϭ 5 per group) were water deprived for 22 h and then allowed 30 min of access to novel almond-flavored water or novel vanilla-flavored water. Flavors were divided among each group. Following the ingestion of flavored water, animals received a bilateral injection of 50 pmol PACAP into the VMN. Normal water was returned 30 min later, and rats were allowed ad libitum access to water for the next 24 h. Afterward, rats were again water deprived for 22 h then allowed 30-min access to the opposite flavor as on day 1 (see Fig.  3A ). Subsequent to access to flavored water, animals received a bilateral vehicle injection into the VMN, and water was again returned for the next 24 h. After both pairing days, the rats were water deprived a final time for 22 h, followed by the test day in which rats were given a two-bottle choice with both flavors for 30 min. A preference ratio was generated from the test day to determine whether rats avoided the flavor paired with the VMN PACAP injection. As a CFA-positive control, another group of animals (n ϭ 5 per group) was included by using lithium chloride (LiCl; 0.15 M; 2% body wt ip), as LiCl is well known to induce malaise. This group of rats was treated similar to the PACAP-treated animals, but received only vehicle injections into the VMN and an intraperitoneal injection of either saline or LiCl.
PAC1R antagonism. Approximately 1 h before dark, rats (n ϭ 6 per group) were weighed and given a bilateral VMN pretreatment of either vehicle or 2.2 nmol of the specific PAC1R antagonist, PACAP6 -38 (Anaspec; Fremont, CA). After 5 min, rats received a second bilateral VMN injection of either vehicle or 220 pmol of PACAP. Food intake was measured manually for the next 3 h, followed by a final 24-h postinjection measurement of food intake and body weight.
In addition to food intake and body weight, changes in hypothalamic ARC neuropeptide mRNA expression were measured. In a similar experimental design, rats (n ϭ 4 per group) received either bilateral VMN injections of vehicle or 220 pmol PACAP, and after 1 h the animals were euthanized via rapid decapitation. Brains were removed quickly and frozen for analysis by using semiquantitative in situ hybridization for pro-opiomelanocortin (POMC), NPY, and agouti-related polypeptide (AgRP) mRNA levels.
Thermogenesis and activity. At the time of cannulation surgery one group of animals (n ϭ 7 per group) was also implanted intraperitoneally with telemetry probes (Mini-Mitter, Bend, OR). Animals were allowed to recover for 5 days before initiation of experiments. Approximately 4 h into the light cycle (0900 h), rats received bilateral VMN injections of vehicle or 50 pmol PACAP and were placed back into their home cage resting on a receiver platform. Telemetric data for core body temperature and spontaneous locomotor activity were collected every 5 min. Core body temperature data were averaged by the hour, and spontaneous locomotor activity data were summed into 1-h bins.
Isolation of Total RNA and Quantitative PCR
Total RNA was isolated from iBAT (n ϭ 8 per group) by Trizol extraction (Invitrogen, Carlsbad, CA). Subsequently, cDNA was constructed with 1 g of total RNA using the Reverse Transcription System (Promega, Madison, WI). Quantitative PCR was performed using a StepOne Real-Time PCR System (Applied Biosystems, Carlsbad, CA), and PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences, Gaithersburg, MD) according to the manufacturer's protocol. Quantification of UCP1 expression was done using a relative standard curve and normalized to the housekeeping gene GAPDH. Primers for UCP1 were 5=-GGTCAGAATGCAAGCACAAA-3= and 5=-TTAGGAGTCGTCCCTTTCCA-3=, and primers for GAPDH were 5=-CTCCCATTCTTCCACCTTTGA-3= and 5=-ATGTAGGC-CATGAGGTCCAC-3=.
In Situ Hybridization
Brains were cryostat sectioned coronally at 12 m, thaw-mounted onto electrostatically clean slides, and stored at Ϫ80°C until postfixed. Prior to hybridization, sections were postfixed in 4% paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M triethanolamine (pH 8.0), and acetylated in triethanolamine containing 0.25% acetic anhydride. Sections were dehydrated through graded ethanol concentrations, delipidated in chloroform, rehydrated to 95% ethanol, and air dried. Standard in vitro transcription methods were used to generate riboprobes against PAC1R (S. Choi, Milwaukee, WI), NPY (S. Sabol, Bethesda, MD), AgRP (M. Schwartz, Seattle, WA), and POMC (C. Wilkinson, Seattle, WA), which were subsequently diluted in hybridization cocktail (Amresco; Solon, OH) with tRNA. Sections were hybridized overnight at 55°C with each 33 P-labeled riboprobe. After hybridization, slides were rinsed in 2 ϫ SSC buffer (pH 7.0). They were treated with RNase A in a 0.5-M sodium chloride, 10 mM Tris, 1 mM EDTA buffer for 30 min at 37°C and then washed in the same buffer without RNase A for 30 min at 37°C. After a subsequent 1 ϫ SSC wash for 15 min at room temperature, slides were stringently washed in 0.5 ϫ SSC for 30 min at 65°C (AgRP, NPY, PAC1R) or 68°C (POMC). Slides were then coated with Kodak autoradiographic emulsion NTB (Rochester, NY) and exposed for 11-22 days depending on the specific riboprobe to produce silver grains. Following standard autoradiography development, NTB emulsion-dipped sections were counterstained with 0.5% cresyl violet.
Image Analysis
Semiquantitative analysis of silver grains was conducted using darkfield microscopy (Axioskop-2; Zeiss, Thornwood, NY) and Ax- iovision image analysis software (Zeiss). Optical transmission was determined from the integration of scattered light captured with a ϫ5 objective and analyzed for intensity of region of interest and total area of reflected light. Background values measured in adjacent areas of tissue not containing hybridized probe were subtracted from all measurements. As such, the reported units are arbitrary and will vary based on the proportion of the area of transmitted light compared with the background. Since the area of distribution for each population of mRNA varies relative to the size of the background, the arbitrary units do not represent relative differences between various brain regions but can be used to measure changes within the same brain region. Analyses of hypothalamic cell groups include the following distances posterior to bregma: the ARC for NPY and AgRP analysis: Ϫ3.1 mm to Ϫ3.6 mm, and POMC analysis: Ϫ2.6 mm to Ϫ3.8 mm.
Immunohistochemistry
Floating coronal sections were incubated in primary antibody against biotin (goat anti-biotin, 1:5,000,000; Vector Labs, Burlingame, CA) or PACAP (rabbit anti-PACAP38, 1:10,000; Bachem, Torrance, CA) for 48 h at 4°C. After washes in PBS, sections were incubated in biotinylated secondary antibody (1:600; Vector labs) for 1 h at room temperature. Next, sections were washed again and incubated in a peroxidase-based avidin/biotin solution using the Vectastain Elite ABC kit (Vector Labs) for 1 h at room temperature. Finally, immunohistochemical staining was visualized using a 3,3=-diaminobenzidine chromogen solution containing nickel.
Statistics
Data are presented as means Ϯ SE, and were analyzed statistically by ANOVA (with repeated measures when appropriate). Tukey honestly significant difference analysis was used for all post hoc group comparisons. Statistical analyses were performed using JMP9 (SAS Institute, Cary, NC). P values Ͻ 0.05 were considered statistically significant.
RESULTS
Feeding Behavior
PACAP injected into the VMN decreased normal feeding as demonstrated by significant main effects by repeated-measures ANOVA (P Ͻ 0.05; Fig. 1A) . At 3 h postinjection, both 25 and 50 pmol doses of PACAP significantly reduced cumulative food intake compared with saline controls, with 25 pmol reducing feeding by 52% (P Ͻ 0.05) and 50 pmol by 80% (P Ͻ 0.01). Furthermore, the 50 pmol dose of PACAP continued to significantly decrease cumulative food intake at 4 h (P Ͻ 0.05) and 6 h postinjection (P Ͻ 0.01). At 18 h after injections, no significant differences were observed across any groups for food intake, but fat pad analysis revealed significant reduction in rWAT weight in animals receiving bilateral 50 pmol PACAP infusion (P Ͻ 0.05; Fig. 1B) . No significant changes in eWAT or iBAT weights were found.
PACAP also significantly reduced food intake following an overnight fast. Bilateral VMN-injected PACAP at a dose of 50 pmol decreased food intake compared with saline controls after 1 h of refeeding during the light cycle (P Ͻ 0.05; Fig. 1C ). 
PACAP Receptor Antagonism
Specific antagonism of PAC1R prior to injection of PACAP completely blocked PACAP-induced decreases in food intake and body weight. Rats received a bilateral pretreatment of saline or PACAP6 -38 ϳ5 min prior to bilateral saline or PACAP injections into the VMN. Significant main effects were observed by repeated-measures ANOVA for food intake (P Ͻ 0.05; Fig. 2A ). Animals receiving vehicle as a pretreatment prior to PACAP showed significantly reduced food intake compared with vehicle controls with a reduction in food intake by 85% (P Ͻ 0.05) over the first hour, 76% (P Ͻ 0.05) over 2 h, and 79% (P Ͻ 0.01) over 3 h. Food intake levels in animals receiving pretreatment with PACAP6-38 prior to PACAP did not differ from vehicle controls. Body weight measurements 24 h after injections showed a significant decrease in the vehicle/PACAP group compared with all other groups (P Ͻ 0.05; Fig. 2B ).
Conditioned Flavor Avoidance
Baseline consumption of the two novel flavors were tested by giving water-deprived naïve rats a two-bottle choice test for 30 min, and measuring intake of both almond-and vanillaflavored water. There was no difference in intake volumes of the two flavors in the baseline experiment (52% almond, 48% vanilla). In the CFA experiment bilateral infusion of 50 pmol PACAP on pairing day 1 was evenly distributed between the two flavors. Furthermore, intake volumes on both pairing days were measured, and rats drank at least 13 ml of flavored water on each pairing day, demonstrating that every animal experienced both flavors prior to the test day. PACAP had no effect on the two-flavor choice test, with animals drinking similar volumes of both the PACAP-paired and vehicle-paired flavor (Fig. 3B) . As a positive control, a separate group of animals receiving intraperitoneal injections of LiCl showed significant avoidance of the LiCl-paired flavor compared with saline treated controls (P Ͻ 0.01; Fig. 3B ).
Thermogenesis and Activity
Bilateral infusions of PACAP into the VMN induced increases in core body temperature with significant main effects by repeated-measures ANOVA (P Ͻ 0.01; Fig. 4A ). This increase in thermogenesis was sustained for up to 7 h after a single injection (P Ͻ 0.05). A separate cohort of animals was used to assess UCP1 mRNA expression via qPCR in iBAT one and 3 h following PACAP injection into the VMN. The results of the qPCR analysis showed a trend to increase iBAT UCP1 mRNA at 1 h and a significant increase at 3 h postinjection (P Ͻ 0.05; Fig. 4C ).
In addition to core body temperature, spontaneous locomotor activity was also increased in PACAP-treated animals, showing significant main effects by repeated-measures ANOVA (P Ͻ 0.05; Fig. 4B ). Activity was significantly increased in PACAP-treated animals from 2-5 h following injections (P Ͻ 0.05).
Neuropeptide mRNA Expression Changes
Semiquantitative in situ hybridization analyses of AgRP, NPY, and POMC mRNA in the hypothalamic ARC following bilateral PACAP injections into the VMN were performed at 1 h postinjection (Fig. 5A) . Quantification of the in situ hybridization revealed a significant increase in arcuate POMC mRNA expression by 52% (P Ͻ 0.05; Fig. 5B ), while no significant differences were observed in either arcuate AgRP or NPY mRNA expression. Figure 6A shows in situ hybridization for PAC1R in the rat brain, confirming high levels of mRNA expression in the hypothalamus (26) . Note the most abundant mRNA expression is found in the medial cell groups of the hypothalamus, which include the DMN, VMN, and ARC (Fig. 6, B and C) .
Hypothalamic PAC1R mRNA Expression and Microinjection Spread
In Figure 7 , immunohistochemical staining of biotinylated PACAP confirmed that the 0.25-l microinjection spread was an optimal volume (Fig. 7A) , as it did not exceed the boundaries of the VMN (Fig. 7, A, right) delineated in the adjacent Nissl stained section (Fig. 7, A, left) . Figure 7B shows PACAP immunoreactivity within the VMN of both neuronal cell bodies and terminals suggesting endogenous PACAP neurotransmission in this region.
DISCUSSION
Bilateral injections of PACAP into the VMN produce a marked reduction in feeding under both normal and foodrestricted conditions. Importantly, this reduction in feeding is not the result of malaise induced by PACAP administration, as there was no aversion observed in the CFA study. Following PACAP injections, animals demonstrated a rapid elevation of both core body temperature and spontaneous locomotor activity. To diminish potential confounding contributions of PAC1R stimulation in surrounding hypothalamic cell groups, we made efforts to confine our PACAP injections within the boundaries of the VMN.
Under normal feeding conditions, injections of either 25 pmol or 50 pmol PACAP per side into the VMN produced significant decreases in cumulative feeding by 3 h postinjection, and lasted for up to 6 h postinjection in animals receiving the higher dose of PACAP. The delayed effect on feeding behavior may be a result of injections administered ϳ2 h prior to lights off, a time when normal food intake is still considerably low, suggesting that PACAP-induced suppression of feeding behavior occurs when feeding behavior is actively stimu- lated. This is further supported by results following an overnight fast, where PACAP injections effectively reduced feeding in food-deprived animals 1 h postinjection, as well as in the PAC1R antagonist study where animals injected with PACAP more proximal to the onset of dark did significantly reduce feeding after 1 h. In addition to influencing feeding behavior, we also observed a significant reduction in rWAT weight at 18 h postinjection with no differences in any of the other fat depots measured. While the reduction in only rWAT is curious and the underlying mechanism still unknown, others have also found rWAT to be more labile during conditions of mild/moderate weight loss (19, 36) . Results obtained following PACAP injections into the VMN closely resemble reports of ventricular PACAP injections (27, 38, 41) , which suggests that the medial hypothalamus may be an important site for PACAP signaling pertaining to energy homeostasis.
PACAP injected intracerebroventricularly in mice robustly decreases food intake and increases energy expenditure, both of which have strikingly similar behavioral patterns to the present study. This is further supported by the dense expression of PAC1R mRNA found in multiple subdivisions of the medial hypothalamus such as the DMN, ARC, and VMN, all of which are major contributors to the control of energy balance (Fig. 6) . Although resulting in different patterns in feeding behavior, lesions of all three hypothalamic subgroups produce obese rats (9, 59) . Obesity following VMN lesions is frequently attributed to metabolic disturbances rather than dramatic changes in feeding behavior (9, 55) . Reports of PACAP-deficient mice also suggest a primary metabolic disruption involving impaired adaptive thermogenesis and abnormal lipid metabolism leading us to initially examine the VMN (20, 21) . To begin identifying the circuitry involving PACAP signaling and energy regulation, we demonstrate that changes in feeding behavior and metabolism following PACAP administration into the VMN can be specifically mediated through the PAC1R. Animals injected with the PAC1R antagonist showed no difference from vehicle-treated controls, while those receiving PACAP alone exhibited profound hypophagia and thermogenesis. As an initial point of observation, the VMN may function as an important, but not exclusive, site of action for mediating the behavioral effects of PACAP signaling. For example, PACAP's actions in the hypothalamus may also include direct or indirect activation of feeding and/or metabolic circuitries involving other hypothalamic cell groups, such as the PVN and ARC. As mentioned earlier, both the PVN and ARC have prominent roles in regulating energy balance and are both known to contain both PAC1Rs and PACAP protein, making these areas attractive targets for future studies.
Previous reports have suggested PACAP-induced hypophagia following intracerebroventricular injection in mice may stimulate melanocortin signaling in the ARC, a well-characterized system known to decrease feeding behavior (41) . Indeed, PAC1Rs have been found on both POMC and NPY containing neurons in the ARC through which activation leads to stimulation of POMC mRNA, c-fos mRNA expression and cytosolic Ca 2ϩ concentrations (39 -42) . However, the present results demonstrate that bilateral injections of PACAP directly into the VMN also increase mRNA expression of POMC in the ARC 1 h after injection without affecting NPY or AgRP expression. Since the vast majority of neurons in the VMN are glutamatergic (18) , activation of PAC1Rs in the VMN could have an excitatory effect on VMN neurons through modulation of AMPA and NMDA currents, as seen in the hippocampus (12, 37, 60) , leading to VMN-mediated excitation of POMC neurons in the ARC (50). Additionally, strong efferent connections from the VMN to the nucleus of the solitary tract (NTS) have been established, and it is possible that stimulation of the VMN by PACAP may cause increased POMC signaling in the NTS as well (4) . In support of the present data, increased POMC signaling in the NTS has also been associated with inhibition of food intake, increased UCP1 expression, and increased wheel-running activity (35, 62) .
While there has been evidence for PACAP stimulation of NPY neurons in the ARC (39, 42) , our data did not demonstrate any effect at 1 h postinjection, possibly arguing for POMC-specific ARC activation by PAC1R-expressing neurons from the VMN. Given the initial constellation of effects produced by intracerebroventricular or ex vivo application of PACAP such as hypophagia, thermogenesis, increased POMC, and NPY signaling, further studies are needed to delineate PACAP's integrated actions on multiple hypothalamic cell groups.
PACAP-treated animals consistently show a greater loss in body weight that cannot fully be attributed to diminished levels of food intake as illustrated in paired-feeding studies (27) . Contributing to the significant loss of body weight following PACAP administration into the VMN is the rapid thermogenesis and increased locomotor activity. Sympathetic thermogenesis independent of physical activity or shivering behavior can be positively correlated with UCP1 content in BAT (28) . At 1 h following PACAP administration into the VMN, increases in iBAT UCP1 mRNA expression did not reach statistical significance, but by 3 h the increase in UCP1 mRNA was significant. Numerous other studies have linked PACAP with autonomic activation, including those showing PACAP synapsing onto PVN neurons, which are known to control autonomic nervous system activity (14, 22, 34) . Also, intracerebroventricular injection of PACAP in anesthetized rats alters autonomic nerve activity (54) , which can be blocked by the melanocortin receptor antagonist SHU9119 (53) , further supporting that PACAPmediated effects on energy are at least partially dependent on melanocortin signaling. Interestingly, PACAP knockout mice are highly thermosensitive and require higher ambient temperatures to survive into adulthood, adding to the evidence that PACAP plays a necessary role in thermoregulation (1, 20, 21 ).
The elevation of spontaneous locomotor activity observed after PACAP injections into the VMN is in contrast to previous reports of ventricular injections in mice where no increases in activity were noted (27) . This may reflect that direct or specific stimulation of the VMN is necessary to alter locomotor circuits, as previous reports have shown that direct injection of GABA A receptor antagonists or kainate produces running activity (43, 61) . Moreover, VMN lesion studies have consistently demonstrated diminished locomotor activity and delayed onset of normal diurnal running activity. Such evidence is congruous with the present study and contributes to the notion that locomotor activity pathways involve the VMN (5, 6) .
Although the VMN is known to express large amounts of PACAP, which appear to be responsive to varying nutritional conditions (27, 41) , the origin of PACAP neurons synapsing onto VMN neurons is not known. In light of the present results, brain regions releasing PACAP into the medial hypothalamus that are sensitive to signals of nutritional status are likely sources of PACAP input into the VMN. One such candidate is the medial amygdala because of its dense PACAP mRNA expression, identified connections to the VMN, and its glucosesensing capability (3, 30, 49, 51, 63) . In addition to extrahypothalamic regions of PACAP input, paracrine/autocrine signaling from VMN neurons themselves may also provide a notable source of PACAP signaling, especially since the VMN is well-known to have extensive intrinsic and contralateral VMN-VMN synaptic circuitry (32, 44) . Further anatomical studies are needed to identify hypothalamic circuitry involving PACAP signaling.
Perspectives and Significance
PACAP injections into the VMN inhibit food intake under normal and fasting conditions by a PAC1R-specific mechanism. Moreover, activation of PAC1R sets in motion a cascade of signals including increased POMC mRNA expression, which may contribute to the thermogenic response of PACAP as ␣-MSH has been shown to be a mediator of PACAPinduced autonomic nerve activity (53) . The source of PACAP innervation of the VMN is currently unknown, but intriguing preliminary evidence provides several brain regions as strong candidates including the VMN itself. These results establish PACAP as a regulator of both feeding behavior and metabolic systems, and its signaling is likely an important component of normal physiological regulation by the VMN.
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